News Agency
Men's Weekly

Skyhawk Therapeutics Has Advanced to the Multiple Ascending Dose Portion of its Phase 1 Study evaluating SKY-0515, a RNA-Targeting Small Molecule for Huntington's Disease

  • Written by PR Newswire
Skyhawk Therapeutics Has Advanced to the Multiple Ascending Dose Portion of its Phase 1 Study evaluating SKY-0515, a RNA-Targeting Small Molecule for Huntington's Disease

SKY-0515 is a small molecule RNA splicing modifier developed through the company's novel SKYSTAR® platform. Having successfully advanced through single asending dose,SKY-0515 is advancing into the Multiple Ascending Dose portion of its phase 1 study. Huntington's disease is a fatal neurological disease with no curative therapies.

WALTH...

Read more: Skyhawk Therapeutics Has Advanced to the Multiple Ascending Dose Portion of its Phase 1 Study...

Aligning Social, Email, and Web Campaigns with Structured Content: Building a Unified Marketing Engine

Few modern marketing campaigns exist in a bubble. A product launch, for example, may kick off with social media buzz, continue into a targeted email campaign, and finish with a conversion-focused web experience. Ideally, all three touchpoints communicate the same... Read more

Writers Wanted



NewsServices.com

Content & Technology Connecting Global Audiences

More Information - Less Opinion